Filter Results
:
(96)
Show Results For
-
All HBS Web
(517)
- Faculty Publications (96)
Show Results For
-
All HBS Web
(517)
- Faculty Publications (96)
- April 2012 (Revised May 2012)
- Case
Merck: Operating Science-Based Business
By: Ananth Raman, Inga Maurer and William Schmidt
Merck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure?
View Details
Keywords:
Science-Based Business;
Management;
Research and Development;
Business and Shareholder Relations;
Operations;
Pharmaceutical Industry;
United States
Raman, Ananth, Inga Maurer, and William Schmidt. "Merck: Operating Science-Based Business." Harvard Business School Case 612-082, April 2012. (Revised May 2012.)
- April 2011
- Teaching Note
Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)
By: Willy Shih and Sen Chai
Teaching Note for 611057.
View Details
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing...
View Details
Keywords:
Multinational Firms and Management;
Patents;
Knowledge Management;
Law Enforcement;
Business and Government Relations;
Research and Development;
Pharmaceutical Industry;
Pharmaceutical Industry;
China
Shih, Willy, Sen Chai, Kamen Bliznashki, and Courtney Hyland. "Office of Technology Transfer - Shanghai Institutes for Biological Sciences." Harvard Business School Case 611-057, March 2011. (Revised June 2012.)
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven...
View Details
Keywords:
Business Model;
Talent and Talent Management;
Innovation and Management;
Leadership;
Growth and Development Strategy;
Product Development;
Organizational Culture;
Research and Development;
Pharmaceutical Industry;
Pharmaceutical Industry;
Switzerland
Pisano, Gary P., Daniela Beyersdorfer, and Ruth Dittrich. "Innovation and Growth at Actelion Ltd." Harvard Business School Case 611-065, March 2011. (Revised February 2012.)
- September 2010
- Teaching Note
Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)
By: Willy C. Shih
Teaching Note for 611009.
View Details
- July 2010
- Case
Metabical: Positioning and Communications Strategy for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara...
View Details
Keywords:
Product Positioning;
Marketing Communications;
Product Launch;
Consumer Behavior;
Pharmaceutical Industry;
United States
Quelch, John A., and Heather Beckham. "Metabical: Positioning and Communications Strategy for a New Weight Loss Drug." Harvard Business School Brief Case 104-240, July 2010.
- April 2010
- Teaching Note
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
Teaching Note for [607008].
View Details
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for...
View Details
Keywords:
Research and Development;
Intellectual Property;
Risk and Uncertainty;
Strategic Planning;
Collaborative Innovation and Invention;
Health Disorders;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- 2010
- Working Paper
Accelerating Energy Innovation: Insights from Multiple Sectors
By: Rebecca Henderson and Richard G. Newell
A combination of concerns about climate change and energy security has recently led to significant increases in public funding for energy R&D. Some commentators are suggesting that these increases need to be sustained, and are advocating for increases of as much as...
View Details
Keywords:
Innovation and Management;
Technological Innovation;
Knowledge Use and Leverage;
Research and Development;
Pollutants;
Climate Change;
Energy Industry
Henderson, Rebecca, and Richard G. Newell. "Accelerating Energy Innovation: Insights from Multiple Sectors." Harvard Business School Working Paper, No. 10-067, February 2010. (Revised February 2011.)
- February 2009
- Teaching Note
Syndexa and Technology Transfer at Harvard University (TN)
Teaching Note for [808073].
View Details
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a...
View Details
Keywords:
Regulations;
Drug Regulations;
Symlin;
Negotiation;
Governing Rules, Regulations, and Reforms;
Resource Allocation;
Negotiation Deal;
Product Development;
Research and Development;
Commercialization;
Pharmaceutical Industry;
United States
Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)
- September 2008
- Case
Pfizer Inc: Building an Innovation Center
By: Stefan H. Thomke and Ashok Nimgade
The case describes Pfizer's efforts to build and run an innovation center in Cambridge, Massachusetts. As the center goes through different periods of leadership and strategic models, its relationship with the corporation and other research sites is explored. The case...
View Details
Keywords:
Innovation and Management;
Innovation Strategy;
Leadership;
Organizational Culture;
Research and Development;
Pharmaceutical Industry;
Cambridge
Thomke, Stefan H., and Ashok Nimgade. "Pfizer Inc: Building an Innovation Center." Harvard Business School Case 609-037, September 2008.
- March 2008
- Case
Novartis AG: Science-Based Business
By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,...
View Details
Keywords:
Innovation and Invention;
Resource Allocation;
Product Development;
Partners and Partnerships;
Research and Development;
Science-Based Business;
Pharmaceutical Industry
Bowen, H. Kent, and Courtney Purrington. "Novartis AG: Science-Based Business." Harvard Business School Case 608-136, March 2008.
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion...
View Details
Keywords:
Demand and Consumers;
Leadership;
Ethics;
Corporate Social Responsibility and Impact;
Decision Choices and Conditions;
Crisis Management;
Health Testing and Trials;
Pharmaceutical Industry;
Pharmaceutical Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- February 2007 (Revised April 2010)
- Case
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
By: Robert S. Huckman, Gary P. Pisano and Mark Rennella
Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression...
View Details
Keywords:
Decision Making;
Measurement and Metrics;
Business Processes;
Organizational Structure;
Research and Development;
Science-Based Business;
Creativity;
Pharmaceutical Industry
Huckman, Robert S., Gary P. Pisano, and Mark Rennella. "Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics." Harvard Business School Case 607-008, February 2007. (Revised April 2010.)
- November 2006 (Revised July 2008)
- Case
Eli Lilly: Developing Cymbalta
By: Elie Ofek and Ron Laufer
Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta...
View Details
Keywords:
Decision Choices and Conditions;
Marketing Strategy;
Product Launch;
Product Development;
Research and Development;
Pharmaceutical Industry
Ofek, Elie, and Ron Laufer. "Eli Lilly: Developing Cymbalta." Harvard Business School Case 507-044, November 2006. (Revised July 2008.)
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic...
View Details
Keywords:
Mergers and Acquisitions;
Growth and Development Strategy;
Product Development;
Research and Development;
Corporate Strategy;
Pharmaceutical Industry;
United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- June 2006
- Teaching Note
Vertex Pharmaceuticals: R&D Portfolio Management (A), (B), and (C) (TN)
By: Francesca Gino and Gary P. Pisano
- Article
Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research
By: Jeffrey Furman, Margaret K. Kyle, Iain Cockburn and Rebecca M. Henderson
Furman, Jeffrey, Margaret K. Kyle, Iain Cockburn, and Rebecca M. Henderson. "Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research." Annales d'économie et de statistique, nos. 79-80 (July–December 2005).
- May 2005 (Revised April 2010)
- Case
GlaxoSmithKline: Reorganizing Drug Discovery (A)
By: Robert S. Huckman and Eli Strick
Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery...
View Details
Keywords:
Mergers and Acquisitions;
Decision Choices and Conditions;
Operations;
Organizational Structure;
Performance Improvement;
Research and Development;
Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (A)." Harvard Business School Case 605-074, May 2005. (Revised April 2010.)